ATE273027T1 - Zusammensetzung zur behandlung von entzündungen - Google Patents

Zusammensetzung zur behandlung von entzündungen

Info

Publication number
ATE273027T1
ATE273027T1 AT99957793T AT99957793T ATE273027T1 AT E273027 T1 ATE273027 T1 AT E273027T1 AT 99957793 T AT99957793 T AT 99957793T AT 99957793 T AT99957793 T AT 99957793T AT E273027 T1 ATE273027 T1 AT E273027T1
Authority
AT
Austria
Prior art keywords
inflammation
composition
treating inflammation
treating
bcc
Prior art date
Application number
AT99957793T
Other languages
English (en)
Inventor
Nigel C Phillips
Mario C Fillion
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Application granted granted Critical
Publication of ATE273027T1 publication Critical patent/ATE273027T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • External Artificial Organs (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
AT99957793T 1998-12-04 1999-12-03 Zusammensetzung zur behandlung von entzündungen ATE273027T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11094398P 1998-12-04 1998-12-04
PCT/CA1999/001156 WO2000033879A1 (en) 1998-12-04 1999-12-03 Method for the treatment of inflammation

Publications (1)

Publication Number Publication Date
ATE273027T1 true ATE273027T1 (de) 2004-08-15

Family

ID=22335783

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99957793T ATE273027T1 (de) 1998-12-04 1999-12-03 Zusammensetzung zur behandlung von entzündungen

Country Status (11)

Country Link
US (1) US6890911B1 (de)
EP (1) EP1135164B1 (de)
JP (2) JP4488626B2 (de)
AT (1) ATE273027T1 (de)
AU (1) AU768327B2 (de)
CA (1) CA2354047C (de)
DE (1) DE69919386T2 (de)
DK (1) DK1135164T3 (de)
ES (1) ES2226464T3 (de)
PT (1) PT1135164E (de)
WO (1) WO2000033879A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR083443A1 (es) 2010-10-13 2013-02-27 Bioniche Life Sciences Inc Una composicion que comprende arn bacteriano y paredes celulares bacterianas, metodo para elaborar dicha composicion y sus usos

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71683A0 (en) * 1984-04-27 1984-09-30 Yeda Res & Dev Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria
JPH0517363A (ja) * 1991-07-11 1993-01-26 Yakult Honsha Co Ltd 抗炎症剤及びそれを含有する化粧料
EP0681479B1 (de) * 1993-01-29 1999-04-28 Vetrepharm, Inc. Immunotherapeutische zubereitung
CN1153574C (zh) * 1997-04-02 2004-06-16 比奥尼斯生命科学公司 细菌细胞壁提取物在制备预防,治疗或排除原生动物或寄生虫疾病的药物组合物上的应用
AU736450B2 (en) * 1997-08-05 2001-07-26 Bioniche Urology Ip Inc. Composition and method for regulating cell proliferation and cell death
CA2366090C (en) * 1999-04-01 2011-05-24 Nigel C. Phillips Composition and method for inducing apoptosis in prostate cancer cells

Also Published As

Publication number Publication date
EP1135164B1 (de) 2004-08-11
JP2002531528A (ja) 2002-09-24
AU768327B2 (en) 2003-12-11
PT1135164E (pt) 2004-11-30
ES2226464T3 (es) 2005-03-16
CA2354047C (en) 2007-08-14
DK1135164T3 (da) 2004-12-20
JP2010001314A (ja) 2010-01-07
JP4488626B2 (ja) 2010-06-23
EP1135164A1 (de) 2001-09-26
US6890911B1 (en) 2005-05-10
DE69919386D1 (de) 2004-09-16
CA2354047A1 (en) 2000-06-15
AU1541100A (en) 2000-06-26
DE69919386T2 (de) 2005-02-17
JP5050148B2 (ja) 2012-10-17
WO2000033879A1 (en) 2000-06-15

Similar Documents

Publication Publication Date Title
DK0762898T3 (da) Cyclodextrinsystem til levering af oligonukleotider til celler
IL180924A0 (en) Method for regulating cell proliferation and cell death
TR200103428T2 (tr) IMPDH enzim inhibitörleri.
ES2150157T3 (es) Piridinas 2-aril sustituidas.
PT1112275E (pt) Novos inibidores heteroaromaticos da frutose-1,6-bisfosfatase
MX9703063A (es) Compuestos de ester y acido boronico, su sintesis y usos.
EP1650193A3 (de) 6-Phenylphenanthridine mit PDE-IV hemmender Wirkung
YU19499A (sh) Benzonaftiridini kao bronhijalni terapeutici
DE60116642D1 (de) Verbindungen mit cytochrom p450ra1 hemmenden aktivität
NZ514408A (en) Bacterial ghosts as carrier and targeting vehicles
PT778844E (pt) Complexos funcionais de metais de terpiridina processos para a sua preparacao e conjugados oligonucleotideos com complexos de metais de terpiridina
ATE273027T1 (de) Zusammensetzung zur behandlung von entzündungen
GB2324091A (en) Metalloproteinase inhibitors
AP2000001937A0 (en) Method for identifying chemical active agents and active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway.
ATE290390T1 (de) Behandlung des harnblasenkrebses durch mycobacterium phlei zellwand
ZA9915B (en) Use of oxidation promoting chemicals in the oxidation of oxidizable galactose type of alcohol configuration containing polymer.
CY1107455T1 (el) Συνθεση και μεθοδος για την προκληση αποπτωσης σε καρκινικα κυτταρα του προστατη
KR970702880A (ko) 신규한 펩티드 활성 물질 및 그의 제조 방법(New Peptide Active Substance And Production Thereof)
ATE235909T1 (de) Biologisch kompatible und biologisch abbaubare zubereitungen enthaltend hyaluronsäure und deren derivate zur behandlung von geschwüren im verdauungsapparat
DE69807200D1 (de) Inklusionskomplexe in waessriger loesung
TR199900905T2 (xx) HTLV-1 enfeksiyonlar�n�n tedavisi i�in bir ilac�n yap�m�nda PKC inhibit�rlerinin kullan�m�.
TR200102019T2 (tr) 3-izoksazolidinonların ve hidroksilamik asitlerin enfeksiyonların tedavisinde kullanılmaları.
RU99116481A (ru) Способ деконтаминации поверхностей
UA32350A (uk) Спосіб лікування гострого інфаркту міокарда
GEP20012440B (en) Biphenylsulfonamide Matrix Metalloproteinase Inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1135164

Country of ref document: EP